The place of VEGF inhibition in the current management of renal cell carcinoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6603025.pdf
Reference31 articles.
1. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1: 1024–1028
2. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase CG, Schwartz B, Piccart M (2005) Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92 (10): 1855–1861
3. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11 (15): 5472–5480
4. Dawson NA, Guo C, Zak R, Dorsey B, Smoot J, Wong J, Hussain A (2004) A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 10 (23): 7812–7819
5. Escudier B, Szczylik C, Eisen T, Oudard S, Stadler WM, Schwartz B, Shan M, Bukowski RM (2005) Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY43-9006) in patients with advanced RCC. ECCO 13, Paris 30th October–3rd November. Presentation
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Successful long-term management of metastatic clear cell renal cell carcinoma with nivolumab: a case report and literature review;ecancermedicalscience;2023-11-30
2. Efficacy of Therapy vs Surveillance in Patients with Resected Early-Stage Intermediate to High-Risk Renal Cell Carcinoma;Kidney Cancer;2023-05-26
3. TOLLIP Protein Expression Predicts Unfavorable Outcome in Renal Cell Carcinoma;International Journal of Molecular Sciences;2022-11-25
4. Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors;Current Oncology Reports;2021-07-16
5. Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant;PLOS ONE;2020-05-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3